Evans Farms Feed in Alvin, Texas, made horse feed with fumonisin above FDA's 1 ppm limit, tied to horse illnesses and one death.
What happened
FDA inspected the feed mill from November 30 to December 9, 2021, as a follow-up to a consumer complaint received October 26, 2021 that multiple horses at two locations became ill, some were hospitalized, and one died after eating food made by the facility. Private testing reportedly showed fumonisin in the implicated horse food, and follow-up testing by the Office of the Texas State Chemist found levels that are redacted in the letter. FDA found the firm had no written food safety plan and did no testing of incoming grains for mycotoxins, and the firm had not responded to the inspection observations (Form FDA 483) by the letter date.
What FDA found
The firm did not prepare or implement a written food safety plan.
21 CFR 507.31The firm had no written hazard analysis.
21 CFR 507.33(a)(2)The firm had no written preventive controls.
21 CFR 507.34(b)The firm lacked written procedures for its supply-chain program, recall plan, monitoring, corrective actions and verification.
21 CFR Part 507 subpart E; 507.38(a)(1); 507.40(a); 507.42(a)(1); 507.49(b)The firm did not test or otherwise evaluate grains and grain co-products for mycotoxins such as aflatoxin, fumonisin and DON.
21 CFR 507.25(b)(2)The firm did not investigate whether it caused fumonisin above FDA's 1 ppm limit in equid feed, nor check other products made with the same corn.
21 CFR 507.25(b)(2)
What FDA wants
FDA asks the firm to write within 15 working days describing the specific steps taken to correct the violations, with supporting documents, and to explain how recurrence will be prevented. If corrections cannot be finished in that time, the firm must give the reason and a completion date.
Who should pay attention
- horse owners and stables buying feed from this mill
- brands and distributors that sell feed made at this facility
- other feed mills that buy corn and grain co-products
This is a summary. Read the original letter on fda.gov.